Sonnet BioTherapeutics to Present at the 40th Annual Cowen Health Care Conference

PRINCETON, NJ / ACCESSWIRE / February 28, 2020 / Sonnet BioTherapeutics, Inc., a company developing innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms, announced today that Jay Cross, Chief Financial Officer, will present a corporate overview at the 40th Annual Cowen Health Care Conference in Boston, MA held March 2-4, 2020.

Sonnet BioTherapeutics Presentation Details:

40th Annual Cowen Health Care Conference
Date: Wednesday, March 4, 2020
Presentation Time: 8:30am ET

About Sonnet BioTherapeutics, Inc.

Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single- or bi-specific action. Known as FHAB™ (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. FHAB™ is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

Sonnet Biotherapeutics Investor Contact

Alan Lada
Solebury Trout
617-221-8006
alada@soleburytrout.com

SOURCE: Sonnet BioTherapeutics, Inc.

ReleaseID: 578349